布瓦西坦
| CAS号 | 357336-20-0 | 货号 | BCP14251 |
| 中文名 | 布瓦西坦 | ||
| 英文名 | Brivaracetam | ||
| 中文别名 | |||
| 英文别名 | UCB 34714;UCB-34714;UCB34714; Briviact; | ||
| 分子式 | C11H20N2O2 | 分子量 | 212.29 |
| 生物活性 | Brivaracetam has been tested in a comprehensive safety pharmacology, toxicology, developmental toxicology, and genotoxicity program. It is of low acute toxicity, target organ for toxic effects is the hepatobiliary tract. Carcinogenicity studies are ongoing. Human pharmacology studies have shown that brivaracetam has a half-life of 8 h and nearly complete bioavailability . CSD episodes were regularly elicited on slices upon delivery of calibrated KCl drops and were recorded via two micropipette electrodes. After control CSDs, the drug was added to the perfusion and five subsequent CSDs were elicited during drug perfusion. Effects were assessed via CSD amplitude (Ampl) and duration at half-amplitude (D(1/2)). BRV, 10 and 32 microM reduced the Ampl and transiently the D(1/2). Levetiracetam, 32 and 100 microM had no effect on either Ampl or D(1/2) . Brivaracetam bound selectively with 20 fold higher affinity than levetiracetam to SV2A . BRV produced a concentration-dependent inhibition of | ||
| 信号通路 | Ion Channel/Membrane Transporter | ||
| 靶 点 | Sodium Channel | ||
结构式
本页面部分数据来自于公开的网络资源,所以瀚香生物不能保证其准确性。
不同批次的产品详情请咨询我们的客服：
- 全国免费电话：400-099-8200
- 在线客服:
瀚香生物（Biochempartner) 的所有产品和服务仅用于科学研究，禁止用于人体和治疗！